GO
Loading...

Eli Lilly and Co

More

  • Midday Glance: Pharmaceuticals companies Friday, 29 Aug 2014 | 1:19 PM ET

    Baxter International Inc. rose$. 08 or. 1 percent, to $74.99. Bristol-Myers Squibb Co. fell$. 01 or percent, to $50.53. Eli Lilly& Co. rose$. 04 or. 1 percent, to $63.15.

  • Early Glance: Pharmaceuticals companies Friday, 29 Aug 2014 | 10:31 AM ET

    Baxter International Inc. fell$. 27 or. 4 percent, to $74.64. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $50.38. Hospira fell$. 09 or. 2 percent, to $54.13.

  • Final Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 43 or. 6 percent, to $74.91. Bristol-Myers Squibb Co. rose$. 29 or. 6 percent, to $50.54. Hospira fell$. 02 or percent, to $54.22.

  • Midday Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 1:19 PM ET

    Baxter International Inc. fell$. 38 or. 5 percent, to $74.96. Bristol-Myers Squibb Co. rose$. 39 or. 8 percent, to $50.64. Hospira rose$. 01 or percent, to $54.25.

  • Early Glance: Pharmaceuticals companies Thursday, 28 Aug 2014 | 10:31 AM ET

    Baxter International Inc. fell$. 47 or. 6 percent, to $74.87. Bristol-Myers Squibb Co. rose$. 24 or. 5 percent, to $50.49. Hospira fell$. 14 or. 3 percent, to $54.10.

  • Final Glance: Pharmaceuticals companies Wednesday, 27 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 19 or. 3 percent, to $75.34. Bristol-Myers Squibb Co. fell$. 52 or 1.0 percent, to $50.25. Hospira rose$. 20 or. 4 percent, to $54.24.

  • Early Glance: Pharmaceuticals companies Wednesday, 27 Aug 2014 | 10:18 AM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $75.03. Bristol-Myers Squibb Co. fell$. 50 or 1.0 percent, to $50.27. Hospira rose$. 04 or. 1 percent, to $54.08.

  • Final Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 6:05 PM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $75.53. Bristol-Myers Squibb Co. rose$. 04 or. 1 percent, to $50.77. Hospira fell$. 56 or 1.0 percent, to $54.04.

  • Midday Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 1:31 PM ET

    Baxter International Inc. rose$. 12 or. 2 percent, to $75.52. Bristol-Myers Squibb Co. fell$. 02 or percent, to $50.71. Hospira fell$. 22 or. 4 percent, to $54.38.

  • Early Glance: Pharmaceuticals companies Tuesday, 26 Aug 2014 | 11:12 AM ET

    Baxter International Inc. rose$. 06 or. 1 percent, to $75.46. Bristol-Myers Squibb Co. rose$. 12 or. 2 percent, to $50.85. Johnson& Johnson rose$. 06 or. 1 percent, to $103.29.

  • Final Glance: Pharmaceuticals companies Monday, 25 Aug 2014 | 6:24 PM ET

    Baxter International Inc. rose$. 36 or. 5 percent, to $75.40. Bristol-Myers Squibb Co. rose$. 55 or 1.1 percent, to $50.73. Johnson& Johnson rose$. 13 or. 1 percent, to $103.23.

  • Early Glance: Pharmaceuticals companies Monday, 25 Aug 2014 | 10:37 AM ET

    Baxter International Inc. rose$. 45 or. 6 percent, to $75.49. Bristol-Myers Squibb Co. rose$. 34 or. 7 percent, to $50.52. Hospira rose$. 28 or. 5 percent, to $54.88.

  • Final Glance: Pharmaceuticals companies Friday, 22 Aug 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 76 or 1.0 percent, to $75.04. Bristol-Myers Squibb Co. rose$. 19 or. 4 percent, to $50.18. Hospira fell$. 14 or. 3 percent, to $54.60.

  • Midday Glance: Pharmaceuticals companies Friday, 22 Aug 2014 | 1:22 PM ET

    Baxter International Inc. fell$. 57 or. 8 percent, to $75.23. Bristol-Myers Squibb Co. rose$. 16 or. 3 percent, to $50.15. Hospira fell$. 13 or. 2 percent, to $54.61.

  • Final Glance: Pharmaceuticals companies Thursday, 21 Aug 2014 | 6:08 PM ET

    Baxter International Inc. rose$. 55 or. 7 percent, to $75.80. Bristol-Myers Squibb Co. fell$. 05 or. 1 percent, to $49.99. Hospira fell$. 17 or. 3 percent, to $54.74.

  • Midday Glance: Pharmaceuticals companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 71 or. 9 percent, to $75.96. Bristol-Myers Squibb Co. fell$. 13 or. 2 percent, to $49.92. Hospira fell$. 12 or. 2 percent, to $54.79.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Lilly psoriasis drug fares well in late-stage test Thursday, 21 Aug 2014 | 8:55 AM ET

    INDIANAPOLIS— Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

  • Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.

  • Lilly psoriasis drug succeeds in late-stage studies Thursday, 21 Aug 2014 | 7:16 AM ET

    Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. Three studies evaluated the drug, ixekizumab, against the generic etanercept and a placebo, in patients with moderate-to-severe plaque psoriasis.